Utama › Limfoma Folikular › Indiana
Kajian klinikal Limfoma Folikular di Indiana
7 kajian untuk Limfoma Folikular sedang mencari peserta di lokasi di Indiana.
Bandar di Indiana
Teks kajian rasmi (Bahasa Inggeris)
5HTP Regulation Of Asthma In Children
- Indiana University, Indianapolis
Mengambil pesertaFasa 2
Umur 8 hingga 18 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT04160910A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Fort Wayne
Mengambil pesertaFasa 3
Umur 18 hingga 130 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06549595A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Investigative Clinical Research of Indiana, Noblesville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06091254SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Indiana University, Indianapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Indiana Blood and Marrow Transplantation, Indianapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Indiana University and Comprehensive Cancer Center, Indianapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT06149286AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- American Oncology Partners, Fort Wayne
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Dis 2025 · NCT05602363Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.